Journal of Medicinal Chemistry · 2004 · 254 citations · 16 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAntiparasitic AgentsEnzyme InhibitionMalariaProtozoal InfectionsProtozoan Host-parasite InteractionsProtozoan PathogenesisAntimalarial Drug DevelopmentCysteine ProteasesIntracellular ProteasesMalaria ParasitesParasitic ProteasesPlasmodium FalciparumProtease InhibitorsTrypanosoma Cruzi Infection
We have synthesized a library of thiosemicarbazones and screened them against three parasitic cysteine proteases, cruzain, falcipain-2, and rhodesain, and against the respective parasite sources of these three proteases, Trypanosoma cruzi, Plasmodium falciparum, and Trypanosoma brucei. The screens identified compounds that were effective against the enzymes and the parasites but also some compounds that were parasiticidal despite a lack of activity against the proteases. Several compounds were effective in killing all tested parasites. These promising lead compounds were tested for general toxicity in mice, and only one produced observable toxicity after 62 h. Our results suggest that thiosemicarbazones represent validated drug leads that kill several species of protozoan parasites through the inhibition of cysteine proteases as well as other novel targets.
16
Human Malaria Parasites in Continuous Culture
William Trager, James B. Jensen · Science · 1976 · 8K citations
Xiaohui Du, Chun Guo, Elizabeth Hansell et al. · Journal of Medicinal Chemistry · 2002 · 383 citations · Full text
Rick A. Finch, Mao‐Chin Liu, Susan P. Grill et al. · Biochemical Pharmacology · 2000 · 367 citations